SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lazlo Pierce who wrote (502)4/16/1998 4:35:00 PM
From: Jim Mac  Read Replies (3) of 1754
 
If PPP is broken up, Visx will have higher revenues since right now, Visx pays into PPP only PRK license fees, not LASIK, which is currently the majority procedure. These Visx PRK fees go to PPP, which then pays back to Visx $140, and $110 to Summit, even though Summit now has astigmatism approval. That's what Visx told me.

Summit also pays its PRK licensing fees into PPP, which then pays back to Summit $125, and Visx $125.

So, without PPP, Visx will get $250 per PRK without having to pay into PPP and lose $110 to Summit (along with current LASIK $250 fee). Visx lasers are doing 70% of all procedures. This means Summit, which is currently getting fees back from PPP disproportionately to its actual procedure count, will no longer be sucking money away from Visx, while Visx will get full attribution for its lasers' productivity.

Additionally, absence of PPP expenses will add to Visx earnings. Summit's too.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext